{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:37:42Z","timestamp":1793363862173,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jaip.2026.03.008","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:50:35Z","timestamp":1774583435000},"page":"1351-1362.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Early and Sustained Efficacy of Depemokimab in Type 2 Asthma: A Pooled Analysis of the SWIFT-1\/-2 Studies"],"prefix":"10.1016","volume":"14","author":[{"given":"Michael E.","family":"Wechsler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reynold A.","family":"Panettieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Buhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitasha","family":"Rupani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Schleich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Muccino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Forth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Kwiatek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vichiendilokkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Howarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2299-868X","authenticated-orcid":false,"given":"David J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2026.03.008_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3132\/pcrj.2007.00002","article-title":"The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK","volume":"16","author":"Lloyd","year":"2007","journal-title":"Prim Care Respir J"},{"key":"10.1016\/j.jaip.2026.03.008_bib2","doi-asserted-by":"crossref","first-page":"00576","DOI":"10.1183\/23120541.00576-2021","article-title":"Type 2 inflammation in asthma and other airway diseases","volume":"8","author":"Maspero","year":"2022","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaip.2026.03.008_bib3","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.jaip.2023.05.028","article-title":"Comprehensive characterization of difficult-to-treat asthma reveals near absence of T2-low status","volume":"11","author":"Rupani","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.03.008_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jaip.2022.09.008","article-title":"Clinical associations of mucus plugging in moderate to severe asthma","volume":"11","author":"Chan","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.03.008_bib6","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fphys.2019.01514","article-title":"Interleukin-5 in the pathophysiology of severe asthma","volume":"10","author":"Pelaia","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.jaip.2026.03.008_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.anai.2021.08.004","article-title":"Interleukin-5 receptor alpha (CD125) expression on human blood and lung neutrophils","volume":"128","author":"Lawrence","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.03.008_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115385","article-title":"The effect of anti-IL5 monoclonal antibodies on regulatory and effector T cells in severe eosinophilic asthma","volume":"166","author":"Bergantini","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jaip.2026.03.008_bib9","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1111\/all.15376","article-title":"Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker-high and -low severe asthma","volume":"77","author":"Khalfaoui","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.03.008_bib10","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/all.15627","article-title":"IL-5 receptor expression in lung fibroblasts: potential role in airway remodeling in asthma","volume":"78","author":"Bajbouj","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.03.008_bib11","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.jaip.2023.05.044","article-title":"Impact of initiating biologics in patients with severe asthma on long-term oral corticosteroids or frequent rescue steroids (GLITTER): data from the international severe asthma registry","volume":"11","author":"Chen","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.03.008_bib12","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/cea.14112","article-title":"Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: a systematic review and meta-analysis","volume":"52","author":"Charles","year":"2022","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2026.03.008_bib13","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0088-2024","article-title":"Biologics in severe asthma: a state-of-the-art review","volume":"34","author":"Gyawali","year":"2025","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jaip.2026.03.008_bib14","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/all.15867","article-title":"Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients","volume":"79","author":"Thomas","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.03.008_bib15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.23822\/EurAnnACI.1764-1489.318","article-title":"Variables predicting clinical remission among adults with severe asthma treated with biologic agents","volume":"56","author":"Yesilkaya","year":"2024","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.03.008_bib16","article-title":"On-treatment clinical remission of severe asthma with real-world longer-term biologic use","volume":"4","author":"Chipps","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaip.2026.03.008_bib17","article-title":"What we know to date about early treatment with biologics in severe asthma: a scoping review about the use of biologics in severe asthma and possible parallels with early rheumatoid arthritis","volume":"7","author":"P\u00e9rez-de Llano","year":"2025","journal-title":"Open Respir Arch"},{"key":"10.1016\/j.jaip.2026.03.008_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2021.100528","article-title":"\"real-life\" management of patients with severe asthma in the biologics era: can we do better?","volume":"14","author":"Charriot","year":"2021","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2026.03.008_bib19","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.anai.2023.07.017","article-title":"Real-world severe asthma biologic administration and adherence differs by biologic: CHRONICLE study results","volume":"131","author":"Ledford","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.03.008_bib20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JAA.S328653","article-title":"Real world biologic use and switch patterns in severe asthma: data from the International Severe Asthma Registry and the US CHRONICLE Study","volume":"15","author":"Menzies-Gow","year":"2022","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2026.03.008_bib21","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2147\/PPA.S198953","article-title":"Patient and physician preferences for attributes of biologic medications for severe asthma","volume":"13","author":"Gelhorn","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jaip.2026.03.008_bib22","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: what is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2026.03.008_bib23","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.medj.2024.10.022","article-title":"Depemokimab, the first ultra-long-acting anti-IL-5 monoclonal antibody for severe eosinophilic asthma","volume":"5","author":"Nolasco","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.jaip.2026.03.008_bib24","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bcp.15002","article-title":"A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma","volume":"88","author":"Singh","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2026.03.008_bib25","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","article-title":"Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype","volume":"391","author":"Jackson","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.03.008_bib26","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jaip.2021.11.026","article-title":"Asthma Daytime Symptom Diary (ADSD) and Asthma Nighttime Symptom Diary (ANSD): measurement properties of novel patient-reported symptom measures","volume":"10","author":"Gater","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.03.008_bib27","first-page":"A1390","article-title":"Measuring meaningful change in patients with asthma using the asthma daytime and asthma nighttime symptom diaries","volume":"209","author":"Keeley","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2026.03.008_bib28","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaip.2020.10.010","article-title":"Long-term therapy response to anti-IL-5 biologics in severe asthma\u2014a real-life evaluation","volume":"9","author":"Eger","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.03.008_bib29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-world effectiveness and the characteristics of a \"super-responder\" to mepolizumab in severe eosinophilic asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2026.03.008_bib30","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2026.03.008_bib31","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02983-2021","article-title":"Cumulative corticosteroid-sparing effect of anti-interleukin-5\/5Ra in eosinophilic asthma","volume":"60","author":"Kroes","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2026.03.008_bib32","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.3390\/jcm12082900","article-title":"A real-world study of achievement rate and predictive factors of clinical and deep remission to biologics in patients with severe asthma","volume":"12","author":"Oishi","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jaip.2026.03.008_bib33","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1164\/rccm.202311-2192OC","article-title":"Exploring definitions and predictors of severe asthma clinical remission after biologic treatment in adults","volume":"210","author":"Perez-de-Llano","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2026.03.008_bib34","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S2213-2600(25)00037-2","article-title":"Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials","volume":"13","author":"Meulmeester","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2026.03.008_bib35","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)11679-5","article-title":"Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial","volume":"360","author":"Green","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2026.03.008_bib36","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.03.008_bib37","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2026.03.008_bib38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13223-018-0248-7","article-title":"Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma","volume":"14","author":"Gao","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2026.03.008_bib39","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1136\/thx.2009.124925","article-title":"Exhaled nitric oxide thresholds associated with a sputum eosinophil count \u22653% in a cohort of unselected patients with asthma","volume":"65","author":"Schleich","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2026.03.008_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.70116","article-title":"Defining the blood cytokine profile in asthma to understand asthma heterogeneity","volume":"13","author":"Bingham","year":"2025","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.jaip.2026.03.008_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","article-title":"Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials","volume":"208","author":"Corren","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2026.03.008_bib42","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5753524","article-title":"Understanding the cellular sources of the fractional exhaled nitric oxide (FeNO) and its role as a biomarker of type 2 inflammation in asthma","volume":"2022","author":"Escamilla-Gil","year":"2022","journal-title":"Biomed Res Int"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826002096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826002096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:27:12Z","timestamp":1781825232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219826002096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2213219826002096"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2026.03.008","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early and Sustained Efficacy of Depemokimab in Type 2 Asthma: A Pooled Analysis of the SWIFT-1\/-2 Studies","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2026.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}